Emgel Articles
GSK signs L86M R&D deal with Biotica
19 January 2009
Warning on ED drug-drug interactions
19 January 2009
Lancet reports antibiotic/cerebral palsy link
29 September 2008
GSK Philippines plans to boost sales 10%
27 June 2005
India NPPA announces drug price revisions
11 April 2005
Canadian web site: all drugs fake, substandard
26 July 2004
Bayer continues to focus on anti-infectives
10 May 2004
India cuts 34 import-content bulk Rx prices
8 March 2004
India revises 22 bulk drug prices
2 June 2003
US antibiotic resistance growth warning
17 March 2003
Zithromax approved by FDA for new otitis media regimen
7 January 2002
Zithromax approved by FDA for new otitis media regimen
18 December 2001
India raises prices of 14 formulations
20 March 2001
Dura gets rights to GW's dermatalogy line
3 October 2000
First approval for B-MS' Tequin heats up antibiotic sector - update
30 December 1999
Medicis Licenses Dermatology Drugs From HMR
3 December 1998
French Generics Prices Cut By Up To 42%
5 October 1998
Chugai Restructures For The 21st Century
28 August 1998
Warnings To Be Added To US Propulsid Labeling
1 July 1998
China: Foreign Drug Investment Categories
10 March 1998
Will New Wave Of Antibiotics Fight Resistance?
23 October 1997
Glaxo Wellcome's Promising New Antibiotic
10 July 1997
Glaxo Wellcome's Promising New Antibiotic
8 July 1997
Lipobay Selected For Large UK Study In Diabetics
24 June 1997
CSM Curbs Terfenadine Use In UK
5 May 1997
Carter-Wallace's Astelin Launched In USA
3 March 1997
HMR Launches Telfast 120 In The UK
3 March 1997
Penederm Signs Dermatological Product Deal With Merck Unit
3 February 1997
HMR Pushes Allegra As It Faces Possible Seldane Ban
20 January 1997
UK Rx Medicines Code Of Practice Report
20 January 1997
Dutch Government Reimbursement Blacklist Rises To 35
9 December 1996
Lack Of New Drugs To Fight Resistant Infections
9 September 1996
Fexofenadine Launched In Its First Market
2 September 1996
USA Clears Pfizer's Zithromax For MAC
24 June 1996
Earnings Growth In Excess of 25% At Elan?
15 April 1996
Lilly's daily Dynabac in France
13 November 1995
India To Reduce Bulk Drug Prices
3 July 1995
USA "No Longer Leads The World In OTCs"
8 May 1995
Synercid And Listeriosis
3 April 1995
Dynabac Effective
24 October 1994
FDA Committees To View OTCs
10 October 1994
Bioglan Launch
5 September 1994
Leuplin Gains Two Additional Indications
1 August 1994
Hoechst Products to Be Boycotted In The USA
18 July 1994
GIST-BROCADES BIDS FOR PIERREL UNIT
23 May 1994
GENTA TO FILE PLA FOR G-101 IN FRANCE
16 May 1994
US PRODUCT NEWS IN BRIEF
18 April 1994
MMD TO FILE SUIT OVER SELDANE FORM
14 March 1994
ABBOTT'S HYTRIN GETS BPH APPROVAL IN USA
11 October 1993
MEDEVA PRODUCT RIGHTS
4 October 1993
BARR LABS REINTRODUCES THREE PRODUCTS
27 September 1993
ZITHROMAX SIMPLIFIES TRACHOMA CONTROL
6 September 1993
PENDING APPLICATIONS IN US CONTINUE TO DWINDLE
19 July 1993
SEMPREX-D BACKED FOR HAYFEVER
17 May 1993
CHINESE FOREIGN INVESTMENT PROJECTS
17 May 1993
BARR LABS HAS 24 PRODUCTS SUSPENDED
15 February 1993
SCHERING-PLOUGH'S CLARITYN GOES OTC
1 February 1993
RPSGB CANDIDATES FOR POM-TO-P SWITCHING
2 November 1992
CARDIZEM CD FOR ANGINA
12 October 1992
ZITHROMAX AND CHLAMYDIA
5 October 1992
ELAN CORP FUTURE LOOKS BETTER THAN EXPECTED
3 August 1992
Taisho experiences profitable year
22 June 1992
DYNAMICS OF THE US ANTIBIOTIC MARKET
22 June 1992
ABBOTT WITHDRAWS TEMAFLOXACIN
15 June 1992
BELMAC EUROPE LAUNCHES EPO PRODS
27 April 1992
BELMAC CORP LOOKS TO USA
17 February 1992
Showing 1-75 of 75 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
